DM
LENZ

Deerfield Management’s LENZ Therapeutics LENZ Stock Holding History

Deerfield Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,353
Closed -$300K – 670
2024
Q2 		$300K Buy
+17,353
New +$303K 0.01% 342
2021
Q4 		– Sell
-129,473
Closed -$14.9M – 143
2021
Q3 		$14.9M Hold
129,473
– – 0.29% 82
2021
Q2 		$27.9M Buy
+129,473
New +$22.6M 0.49% 66

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Deerfield Management's LENZ Position: Q3 2024 in Review

Deerfield Management sold out of LENZ Therapeutics (LENZ) in Q3 2024, closing a stake of 17,353 shares — an estimated $300K sold.

Deerfield Management first reported a position in LENZ in Q2 2021 and held it in 3 quarters. The position peaked at $27.9M in Q2 2021. 78 funds tracked by Wall St. Rank hold LENZ as of Q3 2024.

  • Deerfield Management reported no remaining LENZ Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Deerfield Management sold 17,353 LENZ Therapeutics shares in Q3 2024, an estimated $300K.
  • Deerfield Management first reported a position in LENZ Therapeutics in Q2 2021 and held it in 3 quarters.
  • Deerfield Management's LENZ Therapeutics position peaked at $27.9M in Q2 2021.
  • 78 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2024.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.